Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Decreases By 14.9%

Astria Therapeutics, Inc. (NASDAQ:ATXS) saw a large decline in short interest in the month of December. As of December 15th, there was short interest totalling 2,680,000 shares, a decline of 14.9% from the November 30th total of 3,150,000 shares. Based on an average trading volume of 329,100 shares, the days-to-cover ratio is currently 8.1 days. Approximately 5.6% of the shares of the company are short sold.

Analysts Set New Price Targets

ATXS has been the subject of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a report on Tuesday, December 10th. Oppenheimer lifted their price target on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Astria Therapeutics currently has an average rating of “Buy” and an average price target of $25.60.

Institutional Investors Weigh In On Astria Therapeutics

A number of institutional investors have recently bought and sold shares of the business. FMR LLC raised its stake in shares of Astria Therapeutics by 29.2% during the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after purchasing an additional 1,767,714 shares in the last quarter. RA Capital Management L.P. increased its holdings in Astria Therapeutics by 1.2% in the third quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock worth $56,208,000 after buying an additional 61,457 shares during the last quarter. Vestal Point Capital LP raised its position in Astria Therapeutics by 23.1% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after acquiring an additional 750,000 shares in the last quarter. Millennium Management LLC lifted its stake in Astria Therapeutics by 13.5% in the second quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock valued at $16,763,000 after acquiring an additional 218,518 shares during the last quarter. Finally, Affinity Asset Advisors LLC grew its position in Astria Therapeutics by 15.4% in the second quarter. Affinity Asset Advisors LLC now owns 975,606 shares of the biotechnology company’s stock worth $8,878,000 after acquiring an additional 130,000 shares in the last quarter. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Stock Performance

Shares of NASDAQ:ATXS traded down $0.03 during midday trading on Tuesday, reaching $8.85. The company had a trading volume of 69,863 shares, compared to its average volume of 583,023. The company has a fifty day simple moving average of $10.40 and a two-hundred day simple moving average of $10.73. The firm has a market cap of $499.44 million, a price-to-earnings ratio of -4.23 and a beta of 0.67. Astria Therapeutics has a 1-year low of $6.58 and a 1-year high of $16.90.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.